Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High – Here’s Why

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $241.71 and last traded at $240.93, with a volume of 209368 shares trading hands. The stock had previously closed at $234.64.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KRYS. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday. HC Wainwright reissued a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Bank of America raised their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Citigroup lifted their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Price Performance

The stock’s 50 day simple moving average is $200.23 and its two-hundred day simple moving average is $164.51. The company has a market capitalization of $6.95 billion, a P/E ratio of 35.94 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 13.70% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group lifted its position in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares during the period. Hantz Financial Services Inc. raised its stake in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after buying an additional 179 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after buying an additional 77 shares during the last quarter. Twin Tree Management LP acquired a new position in Krystal Biotech in the first quarter valued at approximately $29,000. Finally, AdvisorNet Financial Inc bought a new position in Krystal Biotech in the third quarter valued at approximately $30,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).